Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Schlenk, Richard Friedrich [VerfasserIn]   i
 Paschka, Peter [VerfasserIn]   i
 Krzykalla, Julia [VerfasserIn]   i
 Weber, Daniela [VerfasserIn]   i
 Kapp-Schwoerer, Silke [VerfasserIn]   i
 Gaidzik, Verena I. [VerfasserIn]   i
 Leis, Claudia [VerfasserIn]   i
 Fiedler, Walter [VerfasserIn]   i
 Kindler, Thomas [VerfasserIn]   i
 Schroeder, Thomas [VerfasserIn]   i
 Mayer, Karin [VerfasserIn]   i
 Lübbert, Michael [VerfasserIn]   i
 Wattad, Mohammed [VerfasserIn]   i
 Götze, Katharina [VerfasserIn]   i
 Horst, Heinz A. [VerfasserIn]   i
 Koller, Elisabeth [VerfasserIn]   i
 Wulf, Gerald [VerfasserIn]   i
 Schleicher, Jan [VerfasserIn]   i
 Bentz, Martin [VerfasserIn]   i
 Greil, Richard [VerfasserIn]   i
 Hertenstein, Bernd [VerfasserIn]   i
 Krauter, Jürgen [VerfasserIn]   i
 Martens, Uwe [VerfasserIn]   i
 Nachbaur, David [VerfasserIn]   i
 Abu Samra, Maisun [VerfasserIn]   i
 Girschikofsky, Michael [VerfasserIn]   i
 Basara, Nadezda [VerfasserIn]   i
 Benner, Axel [VerfasserIn]   i
 Thol, Felicitas [VerfasserIn]   i
 Heuser, Michael [VerfasserIn]   i
 Ganser, Arnold [VerfasserIn]   i
 Döhner, Konstanze [VerfasserIn]   i
 Döhner, Hartmut [VerfasserIn]   i
Titel:Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia
Titelzusatz:early results from the prospective randomized AMLSG 09-09 phase III study
Verf.angabe:Richard F. Schlenk, MD; Peter Paschka, MD; Julia Krzykalla, MSc; Daniela Weber, MSc; Silke Kapp-Schwoerer, MD; Verena I. Gaidzik, MD; Claudia Leis, BSc; Walter Fiedler, MD; Thomas Kindler, MD; Thomas Schroeder, MD; Karin Mayer, MD; Michael Lübbert, MD; Mohammed Wattad, MD; Katharina Götze, MD; Heinz A. Horst, MD, PhD; Elisabeth Koller, MD; Gerald Wulf, MD; Jan Schleicher, MD; Martin Bentz, MD; Richard Greil, MD; Bernd Hertenstein, MD, PhD; Jürgen Krauter, MD; Uwe Martens, MD; David Nachbaur, MD; Maisun Abu Samra, MD; Michael Girschikofsky, MD; Nadezda Basara, MD, DSc; Axel Benner, Dipl-Stat; Felicitas Thol, MD; Michael Heuser, MD; Arnold Ganser, MD; Konstanze Döhner, MD; and Hartmut Döhner, MD
E-Jahr:2019
Jahr:December 18, 2019
Umfang:10 S.
Fussnoten:Gesehen am 08.04.2020
Titel Quelle:Enthalten in: Journal of clinical oncology
Ort Quelle:Alexandria, Va. : American Society of Clinical Oncology, 1983
Jahr Quelle:2019
Band/Heft Quelle:38(2019), 6, Seite 623-632
ISSN Quelle:1527-7755
Abstract:PURPOSEHigh CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial to evaluate GO in combination with intensive induction and consolidation therapy in NPM1-mutated AML.PATIENTS AND METHODSBetween May 2010 and September 2017, patients ≥ 18 years old and considered eligible for intensive therapy were randomly assigned up front for induction therapy with idarubicin, cytarabine, etoposide, and all-trans-retinoic acid with or without GO. The early (P = .02) primary end point of event-free survival (EFS) was evaluated 6 months after completion of patient recruitment.RESULTSFive hundred eighty-eight patients were randomly assigned (standard arm, n = 296; GO arm, n = 292). EFS in the GO arm was not significantly different compared with that in the standard arm (hazard ratio, 0.83; 95% CI, 0.65 to 1.04; P = .10). The early death rate during induction therapy was 10.3% in the GO arm and 5.7% in the standard arm (P = .05). Causes of death in both arms were mainly infections. The cumulative incidence of relapse (CIR) in patients achieving a complete remission (CR) or CR with incomplete hematologic recovery (CRi) was significantly reduced in the GO arm compared with the standard arm (P = .005), with no difference in the cumulative incidence of death (P = .80). Subgroup analysis revealed a significant beneficial effect of GO in female, younger (≤ 70 years), and FLT3 internal tandem duplication-negative patients with respect to EFS and CIR.CONCLUSIONThe trial did not meet its early primary end point of EFS, mainly as a result of a higher early death rate in the GO arm. However, in patients achieving CR/CRi after induction therapy, significantly fewer relapses occurred in the GO compared with the standard arm.
DOI:doi:10.1200/JCO.19.01406
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1200/JCO.19.01406
 Volltext: https://ascopubs.org/doi/10.1200/JCO.19.01406
 DOI: https://doi.org/10.1200/JCO.19.01406
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1694239357
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68562909   QR-Code
zum Seitenanfang